U.S., Feb. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07382726) titled 'Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial' on Jan. 26.
Brief Summary: This research is being done to test a combination of two drugs, Izalontamab Brengitecan (iza-bren) and Adagrasib, in patients with advanced KRAS G12C-mutant NSCLC that hasn't responded to other treatments. The purpose is to see if this combination works better than existing treatments for people whose cancer keeps growing despite KRAS G12C inhibitors.
Study Start Date: July 01, 2026
Study Type: INTERVENTIONAL
Condition:
Non-small Cell Lung Cancer
Intervention:
DRUG: Adagrasib
Given by mouth
DRUG: Iza-bren
Given by IV
...